Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.16B |
| 2 |
Hershey
HSY
|
+$663M |
| 3 |
Lockheed Martin
LMT
|
+$622M |
| 4 |
Altria Group
MO
|
+$525M |
| 5 |
Pfizer
PFE
|
+$499M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.76B |
| 2 |
Merck
MRK
|
+$2.35B |
| 3 |
Automatic Data Processing
ADP
|
+$1.57B |
| 4 |
Blackstone
BX
|
+$1.38B |
| 5 |
Illinois Tool Works
ITW
|
+$1.13B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.85% |
| 2 | Financials | 12.71% |
| 3 | Healthcare | 11.72% |
| 4 | Consumer Discretionary | 10.09% |
| 5 | Industrials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3051
State Street SPDR Portfolio S&P 500 Growth ETF
SPYG
$52.2B
| $471K | ﹤0.01% |
6,434
-511
| -7% | -$35.6K |
|
|
XOMA
3052
DELISTED
Xoma
XOMA
| $470K | ﹤0.01% |
19,560
| – | – |
|
|
FIRY
3053
Firy Inc
FIRY
$146M
| $468K | ﹤0.01% |
72,147
+1,881
| +3% | +$11.5K |
|
3054
Karyopharm Therapeutics
KPTI
$44.4M
| $468K | ﹤0.01% |
20,661
| – | – |
|
3055
Babcock & Wilcox
BW
$1.34B
| $468K | ﹤0.01% |
414,027
-60,752
| -13% | -$75.1K |
|
3056
Viant Technology
DSP
$245M
| $465K | ﹤0.01% |
43,602
| – | – |
|
3057
Tredegar Corp
TG
$267M
| $464K | ﹤0.01% |
71,132
| – | – |
|
3058
Aegon
AEG
$14B
| $462K | ﹤0.01% |
76,413
+3,537
| +5% | +$20.6K |
|
3059
Fennec Pharmaceuticals
FENC
$333M
| $461K | ﹤0.01% |
41,497
| – | – |
|
3060
WPP
WPP
$4.47B
| $461K | ﹤0.01% |
9,734
+2,584
| +36% | +$122K |
|
3061
PepGen
PEPG
$124M
| $460K | ﹤0.01% |
31,290
+3,500
| +13% | +$41.3K |
|
3062
Gencor Industries
GENC
$210M
| $459K | ﹤0.01% |
27,513
| – | – |
|
3063
eHealth
EHTH
$44.4M
| $458K | ﹤0.01% |
76,022
-4,508
| -6% | -$29.9K |
|
|
NGM
3064
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $453K | ﹤0.01% |
284,649
+5,945
| +2% | +$8.82K |
|
3065
MeiraGTx Holdings
MGTX
$1.07B
| $452K | ﹤0.01% |
74,544
| – | – |
|
3066
PMV Pharmaceuticals
PMVP
$59.2M
| $452K | ﹤0.01% |
265,924
+7,397
| +3% | +$13.8K |
|
3067
X4 Pharmaceuticals
XFOR
$378M
| $450K | ﹤0.01% |
10,795
| – | – |
|
|
SRTA
3068
Strata Critical Medical Inc
SRTA
$446M
| $450K | ﹤0.01% |
157,738
-10,595
| -6% | -$32.7K |
|
3069
Maui Land & Pineapple Co
MLP
$357M
| $449K | ﹤0.01% |
20,741
| – | – |
|
3070
RGC Resources
RGCO
$228M
| $449K | ﹤0.01% |
22,196
| – | – |
|
3071
InfuSystem Holdings
INFU
$185M
| $447K | ﹤0.01% |
52,171
| – | – |
|
3072
Asure Software
ASUR
$242M
| $444K | ﹤0.01% |
57,086
-3,489
| -6% | -$31.3K |
|
3073
Vitamin Cottage Natural Grocers
NGVC
$759M
| $444K | ﹤0.01% |
24,581
-1,629
| -6% | -$26.2K |
|
3074
Immunome
IMNM
$2.55B
| $444K | ﹤0.01% |
+17,976
| New | +$365K |
|
3075
FlexShares iBoxx 5-Year Target Duration TIPS Index Fund
TDTF
$1.04B
| $439K | ﹤0.01% |
18,564
+1,155
| +7% | +$27.2K |
|
Similar funds
Charles Schwab's Q1 2024 Portfolio in Review
As of Q1 2024, Charles Schwab held 3,573 positions worth $433B, up 10% from $394B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2024: portfolio turnover was 3.8%. Charles Schwab opened 35 new positions and exited 102, leaving the 3,573-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2024 buy was Schwab Fundamental US Large Company Index ETF: 3,608,604 shares worth $81.1M.
- Charles Schwab added most to Bristol-Myers Squibb in Q1 2024, an estimated $2.16B increase.
- Charles Schwab's biggest Q1 2024 reduction was Broadcom, cutting an estimated $2.76B.
- Charles Schwab fully exited Splunk Inc in Q1 2024, selling an estimated $104M.
- Charles Schwab's ten largest holdings make up 20% of its $433B portfolio in Q1 2024.
- Charles Schwab opened 35 new positions and closed 102 in Q1 2024.
- Charles Schwab's portfolio value rose 10% quarter-over-quarter to $433B.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.